231 related articles for article (PubMed ID: 34482090)
1. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
[TBL] [Abstract][Full Text] [Related]
2. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
[TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
[TBL] [Abstract][Full Text] [Related]
4. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
Ray KK; Molemans B; Schoonen WM; Giovas P; Bray S; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Hovingh GK; Jozwiak JJ; Jukema JW; Kiss RG; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR;
Eur J Prev Cardiol; 2021 Sep; 28(11):1279-1289. PubMed ID: 33580789
[TBL] [Abstract][Full Text] [Related]
5. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
[TBL] [Abstract][Full Text] [Related]
6. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
7. Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.
Reynolds TM; Pottle A; Quoraishi SH
Vasc Health Risk Manag; 2021; 17():227-237. PubMed ID: 34054297
[TBL] [Abstract][Full Text] [Related]
8. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
[No Abstract] [Full Text] [Related]
9. Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
Şimşek B; İnan D; Çınar T; Cagdas-Yumurtaş A; Ozan-Tanık V; Zeren G; İlker-Avcı İ; Yücel-Karabay C; Güngör B; Tokgozoğlu L
Rev Invest Clin; 2021 Nov; 73(3):371-378. PubMed ID: 34098569
[TBL] [Abstract][Full Text] [Related]
10. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
[TBL] [Abstract][Full Text] [Related]
11. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
Vallejo-Vaz AJ; Bray S; Villa G; Brandts J; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Kees Hovingh G; Jozwiak JJ; Jukema JW; Gabor Kiss R; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR; Ray KK;
Cardiovasc Drugs Ther; 2023 Oct; 37(5):941-953. PubMed ID: 35567726
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study.
Gouni-Berthold I; Schaper F; Schatz U; Tabbert-Zitzler A; Fraass U; Sauer S; Ray KK
Atheroscler Plus; 2022 Dec; 50():10-16. PubMed ID: 36643801
[TBL] [Abstract][Full Text] [Related]
13. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
[TBL] [Abstract][Full Text] [Related]
15. Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study.
Petrov I; Dumitrescu A; Snejdrlova M; Zafrir B; Wożakowska-Kapłon B; Fabryova L; Pintarić H; Bridges I; Petkova R
Adv Ther; 2019 Mar; 36(3):608-620. PubMed ID: 30758746
[TBL] [Abstract][Full Text] [Related]
16. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
[TBL] [Abstract][Full Text] [Related]
17. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
[TBL] [Abstract][Full Text] [Related]
18. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
[TBL] [Abstract][Full Text] [Related]
19. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
20. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]